Introduction
Apoptosis plays an important role in the control of many normal physiological processes, such as embryonic development, immune regulation and maintenance of tissue homeostasis (Krammer, 2000) . Decreased sensitivity to apoptotic stimuli is also a trait commonly shared by cancer cells. This feature provides the tumor cells with a survival advantage, facilitating the outgrowth of malignant clones and may also explain a variable susceptibility to various anticancer drugs (Los et al., 1997; Raza, 2000) .
Interferons (IFNs) comprise a family of pleiotropic polypeptides with the common denominator of inhibiting viral replication, making them important in the innate immunity against viral infections. This group of cytokines has also been used clinically in the treatment of a variety of cancers and viral diseases for over 30 years. However, the mechanisms that underlie the antitumor and antiviral activities are still highly unclear, as are the factors responsible for IFN resistance (Grander, 2000) . We and others have clearly shown that interferon-alpha (IFNa) can induce apoptosis in some transformed cell lines as well as in primary tumor cells (Sangfelt et al., 1997; Cai and Jones, 1999; Dai and Krantz, 1999; Thyrell et al., 2002) . Induction of apoptosis is thus a highly attractive mechanism for IFN's antitumoral activity, and it could also play a role in the clearing of virus-infected cells. The detailed molecular background to IFNa-induced apoptosis remains unclear, but we have recently shown that it involves an ordered activation of caspases and the mitochondrial pathway, for example, cytochrome c (cyt c) release, loss of mitochondrial membrane potential (DC m ) as well as caspase-9 activation (Thyrell et al., 2002) .
Although the release of cyt c and other proapoptotic proteins from mitochondria seems to be a common pathway induced by many proapoptotic stimuli, the upstream signaling is probably more agent specific. In order to better understand the molecular signaling leading to the mitochondrial events during IFN-induced apoptosis, we have in the present investigation analysed the effects of IFN on the mediators of the mitochondrial pathway.
In several other systems, it has been demonstrated that release of cyt c from the mitochondrial intramembrane space to the cytoplasm is mediated by the proapoptotic Bcl-2 family proteins Bak and Bax (Wang et al., 2001) . In apoptotic cells, these proteins are suggested to either oligomerize and form pores in the mitochondrial outer membrane, or to interact with the proteins of the mitochondrial megapore (VDAC and ANT) (Marzo et al., 1998; Desagher and Martinou, 2000; Loeffler and Kroemer, 2000; Wei et al., 2000) . Bak and Bax are likely able to substitute for each other, since deficiency for both genes is required to render cells completely resistant to a number of proapoptotic agents, while single knockouts for either gene have far less effect on sensitivity to these compounds . The roles of Bak and Bax in IFN-induced apoptosis have hitherto not been investigated.
Activation and oligomerization of Bak and Bax can be induced by the BH-3-only protein (BOP) Bid , a proapoptotic Bcl-2 family member that is proteolytically cleaved during apoptosis, to its active truncated form by caspase-8 or calpain (Luo et al., 1998; Mandic et al., 2002) . However, other mechanisms for Bak/Bax activation probably exist, since BidÀ/À MEF cells do not show increased resistance to many apoptotic agents . Candidate proteins that might have a similar function as Bid are, for instance, the related BOPs Bik and Bim (Lutz, 2000) . The transduction of the apoptotic signal from the BOPs to Bak and Bax has been shown to be blocked by Bcl-2 overexpression . It is not quite clear how antiapoptotic Bcl-2 family proteins exert this effect, but they are able to bind and sequester proapoptotic Bcl-2 family members of the BOP family as well as Bak and Bax . Furthermore, it has been demonstrated that tumor cells commonly show an increased expression of antiapoptotic Bcl-2 family members like Bcl-2, Bcl-xL and Mcl-1 (Bradbury et al., 1997) , which may be involved both in the malignant transformation process per se as well as causing resistance to various anticancer agents (Consoli et al., 2002) .
The activated and oligomerized or otherwise complexbound Bak and Bax proteins are conformationally modulated, leading to the exposure of an occluded Nterminal sequence (Griffiths et al., 1999; Nechushtan et al., 1999) . Using antibodies specific for these epitopes, modulation of Bak or Bax to their apoptotic conformations can be quantitated as demonstrated in a number of studies (Griffiths et al., 1999; Nechushtan et al., 1999; Bellosillo et al., 2002; Mandic et al., 2002; Panaretakis et al., 2002) . Although Bak and Bax are considered to have overlapping functions, it has been shown in several systems that there is an agent-specific regulation of these two proteins, and that they may serve different functions depending on the proapoptotic stimulus Mandic et al., 2002; Panaretakis et al., 2002) .
We have here studied IFN-induced apoptotic signaling in U266 myeloma and Daudi Burkitt's lymphoma cells, with regard to the kinetics of apoptosis, loss of mitochondrial inner membrane potential, modulation of Bak and Bax as well as other upstream regulatory Bcl-2 family members. To further investigate possible differential regulation of Bak and Bax activities by IFNa, inhibitors of selected pathways were used to assess the involvement of these systems.
Results

Effect of IFNa on apoptosis
In order to establish the time-dependent character of IFNa-induced apoptosis, U266 and Daudi cells were treated with 50 and 300 U/ml IFNa and apoptosis, assessed as annexin V positivity, was analysed after 24 and 48 h (Figure 1a, b) . In the U266 cell line, IFNa caused a dose-and time-dependent increase in the amount of apoptotic cells. This effect was first observed at 24 h of treatment ( Figure 1a) . In Daudi cells, a minute increase in the percentage of apoptotic cells was seen after 48 h of treatment with IFNa ( Figure 1b) .
The involvement of mitochondrial depolarization (loss of DC m ) in IFNa-induced apoptosis was investigated in U266 cells. After the indicated treatments, the amount of TMRE fluorescence that reflects the integrity of mitochondrial inner membrane potential, and annexin V positivity were assessed simultaneously by flow cytometry. Most annexin V-positive cells had low TMRE fluorescence, demonstrating that apoptotic cells exhibit mitochondrial membrane depolarization (Figure 1c) . No significant change in these parameters was observed in IFNa-treated Daudi cells until the 72 h time point (data not shown).
IFNa induces the modulation of Bak and Bax in U266 cells
We utilized Bak and Bax antibodies that recognize the active conformation of these proteins in order to investigate their involvement in IFNa-induced apoptosis. A population of cells with high levels of activated Bak could be detected by flow cytometry after 24 h of treatment with 300 U/ml of IFNa. This population was greatly increased at the 48 h time point (Figure 2a, c) . A similar pattern was observed when the cells were analysed for the activated form of Bax (Figure 2b, c) .
Bak or Bax activation was not seen in Daudi cells treated for 48 h with the same doses of IFNa, correlating well with the lack of increase in annexin V positivity (data not shown).
In order to investigate when in the apoptotic process Bak or Bax are activated, we examined the relation between active caspase-3 and Bak or Bax modulation simultaneously by flow cytometry in U266 cells treated for 48 h with 300 U/ml IFNa. Activation of caspase-3 occurs at the execution phase of apoptosis and coincides with nuclear fragmentation. The results showed that, first, cells with high levels of active Bak were always also positive for active caspase-3 (Figure 3i and ii). This indicates that high levels of active Bak in a cell are not compatible with survival. Second, cells with intermediate levels of active Bak do not always display active caspase-3 (Figure 3i and ii, lower right square), suggesting that Bak activation occurs prior to caspase-3 activation.
Cells with high levels of active Bax were always positive for active caspase-3. However, there was also a cell population with active caspase-3 in the absence of activated Bax (Figure 3iii and iv, upper left square). This indicates that Bax is activated in cells undergoing apoptosis, but that in contrast to Bak, apoptosis may be initiated in the absence of or before activation of Bax.
IFNa induces Bak activation prior to cyt c release and loss of DC m In order to further investigate the sequence of events in IFNa-induced apoptosis, we monitored Bak and Bax activation in relation to cyt c release from mitochondria and loss of DC m . U266 cells were treated with IFNa and double stained for cyt c and Bak or Bax (Figure 4a , b, upper panels) and MitoTracker and Bak or Bax ( Figure  4a , b, lower panels). We analysed the stainings at the single cell level using high-resolution fluorescent microscopy. IFNa treatment for 24 h induced an early activation of Bak prior to the release of cyt c from mitochondria and the loss of DC m (Figure 4a , b, upper panels, respectively). Activated Bak was localized to mitochondria and colocalized with mitochondrial cyt c (Figure 4a , b, upper panels; yellow color for overlap). Activated Bak was also expressed in the apoptotic cells that have already released cyt c and formed apoptotic bodies. Contrary to Bak, Bax activation was only observed in cells where cyt c had already been released and in cells that had lost DC m (Figure 4a , b, lower panels, respectively). Furthermore, active Bax was only found in cells that had condensed nuclei or even already formed apoptotic bodies, indicating that Bax is involved in the later stages of apoptosis (Figure 4a , b, lower panels). These data are also in agreement with the flow cytometry analysis of Bak, Bax and active caspase-3 (see above).
Involvement of Bid in IFNa-induced apoptosis
The BOP member Bid has been shown to be a major player in Bak and Bax activation in some systems , by being an allosteric regulator of both the pro-and antiapoptotic Bcl-2 family of proteins. This protein is thus a potential candidate for causing Bak and Bax activation in the present system. We therefore examined the involvement of Bid in IFNainduced apoptosis in U266 cells by assessing its cleavage to an active, truncated form, tBid. Following treatment with IFNa, some tBid was seen after 24 h, whereas significant cleavage was seen at 48 h ( Figure 5 ). This 
Involvement of caspases in IFNa-induced Bak and Bax modulation
Previous studies in our group have demonstrated that IFNa-induced apoptosis is largely dependent on caspase activation (Thyrell et al., 2002) . In order to investigate the involvement of caspases in the activation of Bak and Bax by IFNa, U266 cells were treated with IFNa in the presence or absence of the pancaspase inhibitor zVAD, and a panel of specific inhibitors of caspases-1 to -10. For these blocking experiments, the optimal concentration of each inhibitor was carefully titrated in order to find a concentration where the inhibitor is active in these cells, but avoiding unspecific inhibition of other caspases (Thyrell et al., 2002) . The activation of Bak and Bax was In order to determine whether any specific caspase could be responsible for causing the inhibition of Bak and Bax activation (seen with the pancaspase inhibitor, zVAD), U266 cells were pretreated for 1 h with each particular inhibitor and then cultured in the presence or absence of IFNa for 48 h. As seen in Figure 6c , in contrast to zVAD, treatment with the specific caspase-8 or -9 inhibitors resulted in a much weaker inhibition of annexin V positivity and mitochondrial depolarization. The addition of caspase-1, -2, -3, -4, -5, -6, -7 and -10 inhibitors was in each case even less effective (data not shown).
Furthermore, we examined the effect of the caspase-8 and -9-specific inhibitors on the activation of Bak and Bax (Figure 6d ). Caspase-8 inhibition led to a minor reduction of Bak and Bax activation, while caspase-9 inhibition had no effect on the activation of these proteins. Thus, neither of these inhibitors was able to mimic the potent blockage of Bak and Bax modulation caused by the pancaspase inhibitor zVAD (Figure 6a ), indicating that there is a caspase other than these two main initiator caspases involved in the activation of Bak and Bax. However, inhibition of caspases-1, -2, -3, -4, -5, -6, -7 and -10 was unable to cause any significant blockage of Bak and/or Bax activation (data not shown). In summary, these data clearly point towards a caspase-dependent mechanism for the activation of Bak and Bax, but the caspase involved seems to be unrelated to caspases-1 to -10.
Involvement of stress-activated pathways in IFNa-induced apoptosis
Proteases unrelated to the caspases have also been shown to have a role in apoptosis regulation in some systems. One example is the Ca 2 þ -activated, stressrelated protease calpain that has been shown to induce Bid cleavage (Mandic et al., 2002) . In order to determine whether this protease could be involved in the IFNainduced activation of Bak and Bax, we pretreated U266 Stress-activated kinase cascades have been implicated as apical activators of the mitochondrial apoptotic pathway, for example, the p38 SAPK kinases that have been shown to initiate the apoptotic pathway in response to several stimuli such as oxidative stress and Figure 4 Bak precedes Bax activation and cyt c release and loss of DC m in IFNa-induced apoptosis. U266 cells were treated for 24 h with 300 U/ml IFNa and double stained for active Bak (green) and cyt c (red) (a, upper panels), Bax (green) and cyt c (red) (a, lower panels), Bak (green) and Mito Tracker (red) (b, upper panels) and Bax (green) and Mito Tracker (red) (b, lower panels). DNA is stained with DAPI (blue). The arrows denote apoptotic cells when Bak and Bax are activated and cyt c has been released from the mitochondria. The asterisks denote cells with normal nuclear morphology, which have activated Bak but not yet released cyt c. These stainings are representative of three independent experiments Activation of Bak/Bax in IFNa-induced apoptosis T Panaretakis et al DNA damage (Ichijo, 1999) . We investigated the involvement of this pathway by using SB203580, an inhibitor of p38 SAPK. SB203580 was added to U266 cells 1 h prior to the addition of IFNa. Thereafter, the cells were cultured for an additional 48 h in the presence or absence of these compounds. SB203580 pretreatment had no effect on either IFNa-induced annexin V positivity or activation of Bak, while it led to a minor decrease in Bax activation (Figure 7b , iv-vi). In summary, calpain and p38 SAPK seem to play a minor role in this system.
Effect of IFNa on antiapoptotic Bcl-2 family members
Mcl-1 and Bcl-xL
The antiapoptotic Bcl-2 family members have overlapping functions, which they exert through interactions with the proapoptotic BOPs and/or direct associations with Bak and Bax Puthalakath and Strasser, 2002) . Downregulation of such antiapoptotic Bcl-2 family members could thus be another cause for Bak and Bax activation. The Bcl-2 levels of U266 cells following IFNa treatment have been previously examined in our laboratory, and were shown to be unchanged (Sangfelt et al., 1997) . In the present study, we investigated the effects of IFNa treatment on the other two antiapoptotic Bcl-2 family members, Mcl-1 and Bcl-xL.
Mcl-1 was found to be gradually upregulated up to 4 h followed by a progressive decrease back to the control levels at the 16 h time point (Figure 8a ). Bcl-xL levels underwent IFN-induced changes with similar kinetics to Mcl-1 (Figure 8b) . Thus, at 16-24 h, a time point at which apoptosis is initiated in these cells, the levels of Mcl-1 and Bcl-xL were back to normal or even lower than in control cells.
Protection from IFNa-induced apoptosis by Bcl-2 overexpression
Overexpression of the antiapoptotic protein Bcl-2 has been shown to protect against a number of apoptotic stimuli acting through the mitochondrial pathway in various experimental systems. In order to determine the relative importance of the mitochondrial pathway, as well as the possible regulatory effect of Bcl-2 on Bak and Bax in the present system, we generated neo-or Bcl-2 stably transfected U266 cells. The Bcl-2 protein levels of clones 7, 8 and 13 are shown in Figure 9a . The effect of IFNa on neo-and Bcl-2 overexpressing U266 clones 7, 8 and 13 was examined by analysing annexin V positivity and mitochondrial depolarization (Figure 9b ). Bcl-2-transfected U266 cells demonstrated an almost complete resistance to IFNa-induced apoptosis compared to the neo-transfected U266, seen both as decreased annexin V positivity and a decreased loss of DC m .
Furthermore, Bak activation was completely abolished in the presence of overexpressed Bcl-2 (Figure 9c , i and ii), whereas there was a clear but less pronounced decrease in Bax activation (Figure 9c , iii and iv) indicating that Bak is primarily responsible for eliciting the IFNa-induced apoptosis. These data also indicate that IFNa induces apoptosis mainly through the mitochondrial pathway, and that Bcl-2 is an upstream modulator of IFN-induced Bak and Bax activation.
Discussion
It has become increasingly clear that the major mechanism of action for most common antitumor agents is the induction of apoptosis in the malignant cell. Cytotoxic agents generally induce apoptosis through the intrinsic pathway, where activation of mitochondrial events leads to the initiation of a conserved pathway by the release of cyt c and other proapoptotic polypeptides such as AIF. However, our knowledge of how various substances induce these events is still incomplete, as is the basis for the great variation in cellular sensitivity to cytotoxic drugs. This means that we currently do not have optimal tools to use these drugs, that is, a scientific base for scheduling and combining drugs or for pretreatment selection of responsive patients.
IFNa is among the few cytokines to have an established role as an effective antitumor agent in some malignant diseases, notably several lymphoid malignancies (Strander and Einhorn, 1996) . The mechanism by Activation of Bak/Bax in IFNa-induced apoptosis T Panaretakis et al which IFN exerts its antitumor activity is still ill-defined, but we and others have shown that IFN can be a potent inducer of apoptosis in some malignant cells (Sangfelt et al., 1997) , forming an attractive hypothesis for how it may act in cancer (Dai and Krantz, 1999; Thyrell et al., 2002) . Favorable results have also been observed using treatment protocols where IFN has been combined with different cytostatic agents (Ludwig and Fritz, 2000; Smalley et al., 2001) . IFN may be predicted to have a different mode of activating the apoptosis machinery in comparison with chemotherapy; this may explain the positive effects observed in such combination protocols.
In order to optimize the use of IFNa in the clinic, a better understanding of the molecular background to IFN-induced apoptosis is warranted. This prompted us to define molecular events leading to IFN-induced apoptosis. We found that IFN induced activation of the two proapoptotic Bcl-2 family members, Bak and Bax, as assessed by measuring conformational changes in these proteins using specific antibodies. We could show that apoptotic cells always had high levels of activated Bak, and that the majority of apoptotic cells contained a high level of Bax in its active conformation suggesting their direct involvement in IFNa-induced cell death. However, the regulation of Bak and Bax activation is distinct, as is probably their role in IFNainduced apoptosis. First, Bak was activated prior to Bax, since a cell population could be found with active Bak but still negative for active caspase-3, while Bax was found only in active caspase-3-positive cells. Using immunohistochemistry, we also demonstrated that Bak activation occurred early in the apoptotic response, prior to the cyt c release and loss of DC m , whereas Bax activation followed these events. Second, cells can probably die by IFNa without activating Bax since there were active caspase-3-positive but Bax-negative cells. Furthermore, a small decrease in Bax-positive cells by the p38 SAPK inhibitor SB203580 did not translate 2002). Our data demonstrate that IFNa treatment leads to caspase-8-mediated cleavage of Bid to its active form, tBid, and that this effect is completely inhibited by the inhibition of this caspase. However, caspase-8 inhibition had only a moderate effect on either Bak or Bax activation and led to a mere 25% reduction in IFNa-induced apoptosis. Therefore, we conclude that caspase-8 and Bid cleavage cannot be fully responsible for Bak or Bax activation in this system. Inhibition of caspase-2 activity using zVDVAD was unable to prevent IFNa-induced activation of Bak and Bax. Since the pancaspase inhibitor zVAD nearly abolished Bak activation and caused significant inhibition of Bax activation, as well as potently reduced apoptosis in our experiments, one or several other caspases are likely to mediate IFN-induced Bak and Bax activation. We attempted to search for the responsible caspase using specific inhibitors of caspase-1, -3, -4, -5, -6, -7, -9 and -10. Pretreatment of cells with none of these inhibitors could, however, mimic the effect of zVAD. Finally, we tested for Ca 2 þ -dependent protease calpain, known to induce Bid cleavage. A specific inhibitor of calpain, calpeptin, had no major effect on either Bak or Bax activation as well as apoptosis induction. In summary, our results imply that IFN-induced apoptosis is initiated by the activation of a caspase, which in turn uses the mitochondria to activate Activation of Bak/Bax in IFNa-induced apoptosis T Panaretakis et al the total caspase cascade in the cell. However, the responsible initiator caspase(s) in the current system remains unknown. Another possible mechanism for Bak and Bax activation might be the downregulation of one or several antiapoptotic Bcl-2 family members. Bcl-2 levels did not change in U266 undergoing apoptosis as we reported previously (Sangfelt et al., 1997) . Interestingly, we found here that two other proteins, Mcl-1 and Bcl-xL, were both transiently upregulated following IFN treatment. Their levels, however, fell to that of control cells already at 16 h, or to even lower levels at the 24 h time point when apoptosis was initiated. The transient increase in the levels of these two proteins might explain the fact that IFN-induced apoptosis is fairly slow in comparison to many other proapoptotic stimuli, in that these proteins may initially protect the cells from proapoptotic signals. The mechanism for their transient upregulation in this system may relate to the presence of STAT-responsive elements in their promoters (Catlett-Falcone et al., 1999; Puthier et al., 2001) .
Bcl-2 is a potent inhibitor of apoptosis that involves the mitochondrial pathway (Ogilvy et al., 1999) . How Bcl-2 prevents apoptosis is still under debate. In our experiments, Bcl-2 overexpression potently inhibited IFNa-induced apoptosis and abolished activation of Bak as well as led to a reduced activation of Bax. This strengthens the notion of the importance of the mitochondrial pathway in IFNa-induced apoptosis. Several Bcl-2-regulated mechanisms could theoretically be involved. A direct binding of Bcl-2 to Bak and Bax might be inhibitory for their activation. It is also possible that Bcl-2 sequesters some factor that is needed for the conformational change of Bak and Bax, for example a BOP . Finally, Bcl-2 can act at the level of initiator caspases, as recently proposed for stress-induced apoptosis (Marsden et al., 2002) . The fact that Bcl-2 can protect cells from IFN-induced apoptosis is also fully in line with data from our previous investigations, demonstrating that the antitumor response to IFNa used as a single drug in patients with multiple myeloma correlated significantly with the expression of the Bcl-2 protein in the primary myeloma cells (Sangfelt et al., 1995) .
The Daudi cell line has been used in numerous studies because of its high sensitivity to IFN-induced cell cycle arrest. With regard to IFN-induced apoptosis, this cell line is clearly less sensitive, with a small increase in the amount of apoptotic cells occurring only at around 72 h of culture in the presence of IFN. The reason for this relative resistance is unclear, but our results show that it correlates well with the inability of IFN to activate Bak and Bax in this cell line.
In summary, the present investigation, for the first time, demonstrates that IFNa-induced apoptosis involves the activation of the two proapoptotic Bcl-2 family members Bak and Bax. Bak was found to be activated prior to Bax and its activation strictly correlates to the amount of apoptosis. The effects of IFNa on Bak/Bax and apoptosis were all inhibited by Bcl-2 overexpression, demonstrating the central role of the mitochondrial pathway in IFNa-induced apoptosis. We could also show that the activation of Bak and Bax required caspase/protease activity. Further studies on upstream modulators of Bak and Bax will help to clarify the signaling events underlying the induction of apoptosis by IFNa.
Materials and methods
Cell lines, culture conditions and treatment
A multiple myeloma cell line, U266 (Sangfelt et al., 1997) , and a Burkitt's lymphoma cell line, Daudi (ATCC, Manassas, USA), were used in these experiments. U266 and Daudi cells were cultured in RPMI (GIBCO, Berlin, Germany) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) (GIBCO, Berlin, Germany), 2 mm l-glutamine, 50 mg/ml streptomycin, 50 mg/ml penicillin and maintained in a humidified incubator under 5% CO 2 at 371C.
The cells were treated with different concentrations of IFNa (recombinant human IFNa2b (Schering-Plough, Kenilworth, NJ, USA)) for 24, 48 and 72 h.
Inhibitors and antibodies
The pancaspase inhibitor z-VAD-FMK (z-Val-Ala-Asp(OMe)-FMK) (50 mm), caspase-8 inhibitor z-IETD-FMK (Z-Ile-Glu(OMe)-Thr-Asp(OMe)-FMK) (10 mm), caspase-9 inhibitor z-LEHD-FMK Á TFA (Z-Leu-Glu(OMe)-His-Asp(OMe)-FMK Á TFA) (1 mm), caspase-3, -7 and -10 inhibitor z-DEVD-FMK (z-Asp(Ome)-Glu-Ome-Val-Asp-FMK) (5 mm), caspase-2 inhibitor (z-VDVAD-FMK) (1 mm), caspase-6 inhibitor (z-VAID-FMK) (1 mm), caspase-1 and -4 inhibitor (Z-YVAD-FMK) (2 mm) and caspase-1 and -5 inhibitor (Z-WEHD-FMK) (2 mm) were obtained from Enzyme System Products (Livermore, USA). The p38 SAP kinase inhibitor SB203580 (Calbiochem) was used at 10 mm. The calpain inhibitor calpeptin (Alexis Biochemicals) was used at 10 mm.
The antibody against Bak is a mouse monoclonal against amino acids 1-52 of Bak (AM03, clone TC100; Oncogene Research Products). The antibody against Bax is a mouse monoclonal against amino acids 12-24 of Bax (clone 6A7; Pharmingen-Becton Dickinson). The antibody against Bid is from Cell Signaling Technology. The antibodies against cyt c and Bcl-xL were purchased from Pharmingen-Becton Dickinson. The antibody against Mcl-1 is from Dako. The cyt c antibody was biotinylated using an EZ-Link Sulfo-NHS biotinylation kit from Pierce.
Assessment of apoptosis
Redistribution of plasma membrane phosphatidyl serine is a marker of apoptosis and was assessed using annexin V FLUOS (Boehringer Mannheim) according to the manufacturer's protocol. Briefly, 10 6 cells were collected, washed in phosphate-buffered saline (PBS), pelleted and resuspended in incubation buffer (10 mm HEPES/NaOH, pH 7.4, 140 mm NaCl, 5 mm CaCl 2 ) containing 1% annexin V. The samples were kept in the dark and incubated for 15 min prior to the addition of another 400 ml of incubation buffer and analysis by a FACS Calibur flow cytometer (Becton Dickinson) using Cell Quest software.
Reduction in mitochondrial membrane potential, DC m , is a typical feature of apoptotic cells. In order to detect IFNainduced changes in DC m , cells were stained with tetramethylrhodamine ethyl ester perchlorate (TMRE; Molecular Probes Inc.). Briefly, 10 6 cells were cultured in the presence or absence of IFNa for different time periods, whereafter TMRE was added to a final concentration of 25 nm, a concentration that remained throughout the experiment. After incubation for 30 min, cells were pelleted and washed in PBS and TMRE once, and then incubated for 10 min in the dark in 100 ml of incubation buffer (10 mm HEPES/NaOH pH 7.4, 140 mm NaCl, 5 mm CaCl 2 , 25 nm TMRE) containing 1% annexin V FLUOS. Prior to flow cytometric analysis, another 400 ml of incubation buffer was added. For assessment of caspase-3 activation, see below.
Flow cytometric analysis of Bak and Bax activation
Upon induction of apoptosis, the proapoptotic Bax and Bak proteins undergo conformational changes that expose otherwise inaccessible N-terminal epitopes. In the present study, we have used two antibodies shown to specifically recognize these epitopes (Griffiths et al., 1999; Nechushtan et al., 1999) . Using a fluorescein isothiocyanate (FITC)-conjugated secondary antibody, the increases in accessibility of these epitopes can be monitored by flow cytometry. At specific time points following IFNa treatment, cells were harvested and fixed in paraformaldehyde (0.25%, 5 min), washed three times in PBS, and incubated for 30 min with primary antibody diluted 1 : 50 in PBS containing digitonin (100 mg/ml). After three washes in PBS, cells were incubated with FITC-labeled anti-mouse antibody for 30 min, washed twice and resuspended in PBS. Negative controls using an irrelevant primary antibody (rabbit anti-MEKK1) were also prepared. Cells (10 000/sample) were analysed on a FACS Calibur flow cytometer using Cell Quest software. For quantitation and comparison, median fluorescence intensity values were calculated, also by Cell Quest software.
Immunocytochemistry
For Bax/ or Bak/cyt c double staining, cells were cytospun onto glass slides, fixed in 3% paraformaldehyde (PFA), washed once with PBS and permeabilized using digitonin diluted in PBS for 10 min. After one wash in PBS, the staining proceeded as follows: anti-Bax or anti-Bak monoclonal antibodies (mAbs), three washes in PBS, rabbit-anti-mouse FITC-conjugated secondary antibodies, three washes in PBS, normal mouse serum (Chemicon Int.), biotinylated anticyt c mAb (clone 6H2.B4, pharmingen), three washes in PBS followed by Texas red streptavidin (Vector Lab., Inc.). Slides were mounted using Vectashield with DAPI (Vector Lab., Inc.).
For mitochondrial stainings, cells were incubated for 30 min in normal growth medium containing 5 mm MitoTracker (Mol. Probes, Inc.). Cells were then cytospun on glass slides, fixed in 3% PFA for 20 min, permeabilized using digitonin diluted in PBS for 10 min and stained with anti-Bax (clone 6A7, Pharmingen) or anti-Bak (Ab-1, Oncogene Research Products) antibodies for 1 h at RT, followed by rabbit-anti-mouse FITCconjugated antibodies (DAKO). The images were recorded on a DAS Leitz DM RB microscope with a Hamamatsu C4880 dual-mode cooled CCD camera and further processed using Photoshop software (Adobe).
Flow cytometric analysis of active caspase-3
Caspase-3 is a key effector protease that is activated in cells undergoing apoptosis. Detection of the active form of caspase-3 by flow cytometry was used to assess apoptosis induced by IFNa. Briefly, 10 6 cells were cultured in the presence or absence of IFNa and harvested. The cells were washed twice with PBS and resuspended in cytofix/cytoperm solution (Becton Dickinson) for 20 min on ice. After two washes with perm/wash buffer (Becton Dickinson) at room temperature, the pellets were resuspended in perm/wash buffer containing the FITC-conjugated monoclonal active caspase-3 antibody (Becton Dickinson) and incubated for 30 min at room temperature. Each sample was then washed with perm/wash buffer and analysed by flow cytometry. Results are shown both as frequency histograms and, after quantitation based on median fluorescence intensity values, also as fold induction in bar charts.
Western blot analysis
For Western blot analysis 5 Â 10 6 cells were prepared by lysis through sonication in LSLD buffer (50 mm HEPES at pH 7.4, 50 mm NaCl, 10% glycerol, 0.1% Tween 20, 0.3 mm Naorthovanadate, 50 mm NaF, 80 mm glycerophosphate, 20 mm Na-pyrophosphate, 1 mm DTT, 1 mm PMSF, 10 mg/ml each of leupeptin and antipain, 5 mg/ml aprotinin and 100 mg/ml each of benzamidine hydrochloride and soybean trypsin inhibitor). A total of 40 mg of protein was loaded in each well for resolution on 12% SDS-PAGE and electroblotting to PVDF membranes by semidry transfer. The membranes were incubated for 1 h each with the appropriate primary and secondary antibodies. Bands were visualized by ECL according to the manufacturer's protocol (Amersham).
Transfections
U266 cells were transfected by electroporation using a construct encoding a full-length BCL-2 cDNA in a pCDNAneo vector. The empty pCDNA vector was used to produce a neomycin-resistant pool for control experiments. A total of 5 Â 10 6 cells were resuspended in 300 ml of complete RPMI medium (containing glutamine, antibiotics and 10% FCS) and electroporated in a 0.4 cm cuvette at 250 V, 960 mF using Gene Pulser from Bio-Rad. In all 10 mg of each plasmid DNA was, used. Right after the pulse, the cells were diluted with complete RPMI medium to a concentration of 4 Â 10 5 /ml. After 2 days, the medium was replaced with RPMI containing 500 mg/ml of G418. The neomycin-resistant pool of living cells was separated on a Ficoll gradient 1 week later, and cells were cloned in a 96-well plate by limiting dilution. Bcl-2 expression was analysed by immunostaining and Western blotting.
